Summarized by Masters of Longevity from Startupticker.ch.
Announcement of a global co-development and co-promotion deal to advance a claudin-1 targeted therapy for rare kidney and liver diseases.
Key Takeaways
- CSL will pay Alentis an initial US$355 million and up to US$1.2 billion in commercial milestones.
- CSL will fully fund completion of the ongoing Phase 2 RENAL trial and planned Phase 3 and other Phase 2 trials.
- If commercialised, global profits will be shared 55% to CSL and 45% to Alentis.
